BR112015022819A8 - método para a preparação de um taxano lipossomal, composição compreendendo um lipossoma e taxano lipossomal - Google Patents

método para a preparação de um taxano lipossomal, composição compreendendo um lipossoma e taxano lipossomal Download PDF

Info

Publication number
BR112015022819A8
BR112015022819A8 BR112015022819A BR112015022819A BR112015022819A8 BR 112015022819 A8 BR112015022819 A8 BR 112015022819A8 BR 112015022819 A BR112015022819 A BR 112015022819A BR 112015022819 A BR112015022819 A BR 112015022819A BR 112015022819 A8 BR112015022819 A8 BR 112015022819A8
Authority
BR
Brazil
Prior art keywords
liposome
taxane
lipid
preparation
composition
Prior art date
Application number
BR112015022819A
Other languages
English (en)
Other versions
BR112015022819A2 (pt
Inventor
Blackledge James
Lanahan Grapperhaus Margaret
D Mcghee William
Original Assignee
Mallinckrodt Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Llc filed Critical Mallinckrodt Llc
Publication of BR112015022819A2 publication Critical patent/BR112015022819A2/pt
Publication of BR112015022819A8 publication Critical patent/BR112015022819A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo patente de invenção: "formulações modificadas de lipossoma de docetaxel". a presente invenção refere-se a composições para o tratamento do câncer. as composições incluem lipossomas que contêm um lipídeo de fosfatidil colina, um esterol, um peg-lipídeo, e um taxano. o peg-lipídeo constitui de cerca de 2 a cerca de 8% molar dos lipídeos no lipossoma. o taxano é docetaxel esterificado na posição 2'-o com um ácido heterociclil-(alcanoico c2-5). os métodos para a preparação de taxanos lipossomais e o tratamento do câncer com taxanos lipossomais também são divulgados.
BR112015022819A 2013-03-13 2014-03-13 método para a preparação de um taxano lipossomal, composição compreendendo um lipossoma e taxano lipossomal BR112015022819A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361779902P 2013-03-13 2013-03-13
PCT/US2014/026483 WO2014160392A1 (en) 2013-03-13 2014-03-13 Modified docetaxel liposome formulations

Publications (2)

Publication Number Publication Date
BR112015022819A2 BR112015022819A2 (pt) 2017-07-18
BR112015022819A8 true BR112015022819A8 (pt) 2019-11-26

Family

ID=50686145

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022819A BR112015022819A8 (pt) 2013-03-13 2014-03-13 método para a preparação de um taxano lipossomal, composição compreendendo um lipossoma e taxano lipossomal

Country Status (8)

Country Link
US (1) US20140271822A1 (pt)
EP (1) EP2968145A1 (pt)
JP (3) JP6294456B2 (pt)
CN (1) CN105188675A (pt)
BR (1) BR112015022819A8 (pt)
CA (1) CA2903255C (pt)
MX (1) MX2015012201A (pt)
WO (1) WO2014160392A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015022819A8 (pt) * 2013-03-13 2019-11-26 Mallinckrodt Llc método para a preparação de um taxano lipossomal, composição compreendendo um lipossoma e taxano lipossomal
CN104622810B (zh) * 2015-02-15 2018-06-08 中国药科大学 一种稳定型难溶性抗肿瘤药物脂质体及其制备方法
WO2016134066A1 (en) * 2015-02-17 2016-08-25 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof
WO2016161428A1 (en) * 2015-04-02 2016-10-06 The Research Foundation For The State University Of New York Serum-stable compositions and methods for light-triggered release of materials
EP3352733A1 (en) * 2015-09-21 2018-08-01 Mallinckrodt LLC Improved stability of liposome formulations and uses thereof
JP6697541B2 (ja) * 2016-01-07 2020-05-20 ウエスタン ユニバーシティ オブ ヘルス サイエンシーズ 膀胱癌処置のための処方物
US20190070113A1 (en) * 2016-03-16 2019-03-07 Merrimack Pharmaceuticals, Inc. Treating Ephrin Receptor A2 (Epha2) Positive Cancer with Targeted Docetaxel-Generating Nano-Liposome Compositions
AU2017232634A1 (en) * 2016-03-16 2018-09-13 Merrimack Pharmaceuticals, Inc Nanoliposomal Targeting of Ephrin Receptor A2 (Epha2) And Related Diagnostics
SG11201807148RA (en) * 2016-03-16 2018-09-27 Merrimack Pharmaceuticals Inc Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositions
EP3500312B1 (en) * 2016-08-18 2024-04-10 Troy Bremer Delivery of urea to cells of the macula and retina using liposome constructs
CN107951861B (zh) * 2016-10-17 2020-12-01 南京绿叶制药有限公司 一种脂质纳米粒膜材料组合物
WO2018106980A1 (en) * 2016-12-08 2018-06-14 Mallinckrodt Llc Liposomal elinafide formulations and uses thereof
US20190008987A1 (en) 2017-07-07 2019-01-10 Drexel University Voltage-Activated Therapeutic, Diagnostic, And/Or Theranostic Constructs
CN110496103B (zh) * 2018-05-18 2022-05-10 上海维洱生物医药科技有限公司 一种多西他赛棕榈酸酯脂质体及其制备方法
JP7482487B2 (ja) * 2018-09-13 2024-05-14 タイワン リポソーム カンパニー リミテッド 鎮静薬を含む徐放性医薬組成物およびその使用
CN113015520A (zh) * 2018-10-17 2021-06-22 台湾微脂体股份有限公司 含有免疫调节剂的缓释药物组合物及其用途
CN110571005B (zh) * 2019-09-27 2021-01-01 广西科技大学 一种固定化金属离子-磁性脂质体及其制备方法和应用
CN111004195B (zh) * 2019-12-03 2022-01-28 沈阳药科大学 卡巴他赛弱碱性衍生物及其制剂
CN114588279B (zh) * 2022-03-31 2023-10-20 重庆医科大学附属第二医院 一种多功能纳米分子探针及其制备方法和其作为视网膜母细胞瘤诊疗制剂的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US6107332A (en) 1995-09-12 2000-08-22 The Liposome Company, Inc. Hydrolysis-promoting hydrophobic taxane derivatives
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6541508B2 (en) 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
AU2003287526A1 (en) * 2002-11-06 2004-06-03 Protein-stabilized liposomal formulations of pharmaceutical agents
US20070003607A1 (en) * 2003-09-02 2007-01-04 Vibhudutta Awasthi Neutral liposome-encapsulated compounds and methods of making and using thereof
AU2005295072A1 (en) * 2004-10-08 2006-04-20 Alza Corporation Method of insertion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves
MX2007013200A (es) * 2005-04-22 2008-03-24 Johnson & Johnson Composicion de inmunoliposoma para el direccionamiento hacia un receptor de la celula her2.
CN101485629B (zh) * 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
CN104622809B (zh) 2008-05-23 2019-04-19 英属哥伦比亚大学 用于脂质体纳米颗粒的修饰的药物
CN102038641B (zh) * 2009-10-26 2013-04-17 石药集团中奇制药技术（石家庄）有限公司 一种外层经亲水聚合物修饰的脂质体药物的制备方法
US20120231066A1 (en) * 2011-01-24 2012-09-13 Henry John Smith Multi-drug liposomes to treat tumors
CN103338747A (zh) * 2011-01-28 2013-10-02 皇家飞利浦电子股份有限公司 用于局部释放亲水性前药的载体
CN102188713A (zh) * 2011-05-09 2011-09-21 中山大学 一种肝靶向药物组合物及其制备方法
BR112015022819A8 (pt) * 2013-03-13 2019-11-26 Mallinckrodt Llc método para a preparação de um taxano lipossomal, composição compreendendo um lipossoma e taxano lipossomal

Also Published As

Publication number Publication date
CA2903255A1 (en) 2014-10-02
CA2903255C (en) 2018-08-28
US20140271822A1 (en) 2014-09-18
JP2017214433A (ja) 2017-12-07
JP2019006815A (ja) 2019-01-17
WO2014160392A1 (en) 2014-10-02
JP6294456B2 (ja) 2018-03-14
EP2968145A1 (en) 2016-01-20
MX2015012201A (es) 2015-11-30
BR112015022819A2 (pt) 2017-07-18
CN105188675A (zh) 2015-12-23
JP2016513655A (ja) 2016-05-16

Similar Documents

Publication Publication Date Title
BR112015022819A8 (pt) método para a preparação de um taxano lipossomal, composição compreendendo um lipossoma e taxano lipossomal
BR112015022476A2 (pt) composições de oxaliplatina de lipossoma para terapia de câncer
BR112015022415A2 (pt) composições de cisplatina lipossômica para terapia contra câncer
CY1123945T1 (el) Στοματικα σκευασματα αμεσης απελευθερωσης για υποκατεστημενες κιναζολινονες
BR112014010291A2 (pt) composições de lipossoma combinacionais para terapia de câncer
BR112014010206B8 (pt) composto derivado de piridopirazina, composição farmacêutica, e, uso de um composto
BR112013005679A2 (pt) imidazopiridazinas substituídas
BR112015032432A2 (pt) Conjugado de oligonucleotídeo antisense, oligômero, composição farmacêutica, uso de um oligômero ou conjugado de oligonucleotídeo antisense ou composição farmacêutica, método de tratamento da hipercolesterolemia ou de distúrbios relacionados e método in vivo ou in vitro
BR112014010183B8 (pt) Composto, composição farmacêutica, produto, e, uso de um composto
BR112013026308A2 (pt) Compostos de benzeno substituídos
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
BR112015008447A2 (pt) métodos para tratar câncer
BR112014004687A2 (pt) imidazopiridazinas amino-substituídas
BR112012009376A2 (pt) composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso
AR095962A1 (es) Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos
BR112012016879A2 (pt) Derivados de fumarato de acido graxo e seus usos
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
BR112012010706A2 (pt) composto, composição farmacêutica, combinação do produto farmacêutico, uso de um composto, e, métodos para o tratamento de uma doença ou condição, e para inibir um bromodomínio
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
BR112015008480A2 (pt) compostos de benzeno substituído
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
AR091006A1 (es) Formulaciones de testosterona proliposomal
CO6501190A2 (es) Vacuna de pcsk9
BR112015000174A2 (pt) método para o tratamento da artrite

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2623 DE 13/04/2021.